Moderna (MRNA) Projected to Announce Earnings on Friday

Moderna (NASDAQ:MRNA) is expected to release its Q3 2026 results before the market opens on Friday, November 6th. Analysts expect the company to announce earnings of ($1.10) per share and revenue of $890.25 million for the quarter. Interested persons may review the information on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, November 6, 2026 at 8:00 AM ET.

Moderna Trading Up 13.1%

Shares of Moderna stock opened at $258.38 on Thursday. The firm has a 50-day simple moving average of $187.78 and a two-hundred day simple moving average of $89.46. Moderna has a fifty-two week low of $22.28 and a fifty-two week high of $258.72. The company has a current ratio of 2.29, a quick ratio of 2.18 and a debt-to-equity ratio of 0.09.

Insider Activity at Moderna

In related news, President Stephen Hoge sold 40,294 shares of Moderna stock in a transaction dated Monday, September 14th. The stock was sold at an average price of $144.13, for a total value of $5,807,574.22. Following the sale, the president directly owned 1,525,858 shares in the company, valued at approximately $219,921,913.54. The trade was a 2.57% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Klinger sold 3,471 shares of the business’s stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $139.95, for a total value of $485,766.45. Following the sale, the insider owned 74,129 shares of the company’s stock, valued at approximately $10,374,353.55. This trade represents a 4.47% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders have sold 197,251 shares of company stock valued at $33,875,904. 10.80% of the stock is owned by corporate insiders.

Moderna News Roundup

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna said its mRNA-2808 multiple myeloma data will be presented orally at the American Society of Hematology meeting. The early results included four confirmed responses among 11 heavily pretreated patients, supporting interest in the therapy’s approach of using mRNA to produce three cancer-targeting agents. Article: Moderna Soars 8% on Early Multiple Myeloma Data
• Positive Sentiment: A WHO technical advisory group recommended advancing Moderna’s investigational Bundibugyo ebolavirus vaccine, mRNA-1469, into a Phase 2/3 efficacy study in the Democratic Republic of the Congo, following encouraging preclinical and Phase 1 results. Article: Moderna Advances Investigational Bundibugyo Ebolavirus Vaccine Toward Phase 2/3 Study
• Positive Sentiment: A separate Moderna–Merck cancer vaccine program showed a 42% reduction in the risk of death and melanoma recurrence when combined with Keytruda in a late-stage trial, adding to the potential value of Moderna’s oncology pipeline. Article: Moderna’s Cancer Vaccine Is Incredibly Promising, but This Could Be a Major Obstacle to Its Success
• Neutral Sentiment: The myeloma findings are preliminary, based on a small group of patients, and the treatment is still investigational; the ASH presentation may provide more detail, but the data do not yet establish broader or lasting benefit. Article: Moderna Announces Oral Presentation of mRNA-2808 Clinical Data

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the company. The Goldman Sachs Group upped their price target on Moderna from $120.00 to $137.00 and gave the stock a “neutral” rating in a report on Thursday, October 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Moderna in a report on Wednesday, September 9th. Berenberg Bank boosted their price objective on Moderna from $45.00 to $100.00 and gave the company a “hold” rating in a research report on Friday, September 11th. Deutsche Bank Aktiengesellschaft initiated coverage on Moderna in a research report on Friday, August 28th. They issued a “hold” rating and a $125.00 price objective for the company. Finally, Bradesco Corretora raised Moderna to an “outperform” rating in a research note on Friday, August 28th. Six investment analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and four have issued a Sell rating to the stock. Based on data from MarketBeat, Moderna presently has an average rating of “Hold” and a consensus target price of $107.10.

About Moderna

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can stimulate immune responses or support the treatment of disease. The company’s research programs span infectious diseases, immuno-oncology, rare diseases, autoimmune conditions and other therapeutic areas.

Moderna’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults.